AZD2461: Novel PARP Inhibitor for Advanced Breast Cancer Research

Executive Summary: AZD2461 is a potent PARP inhibitor with an IC50 of 5 nM for PARP enzymes involved in DNA repair and cell death, showing cytotoxicity in human breast cancer cell lines MCF-7 and SKBR-3 through G2 phase cell cycle arrest and S-phase reduction (Schwartz 2022). It demonstrates complete inhibition of PARP activity in vivo for several hours post-administration, with full recovery of PAR levels after 24 hours in mouse KB1P tumor models. AZD2461 uniquely bypasses P-glycoprotein-mediated drug resistance, contrasting with first-generation PARP inhibitors such as olaparib. Long-term administration in mice doubles median relapse-free survival compared to controls and is well tolerated. APExBIO supplies AZD2461 (A4164), enabling standardized research applications in DNA damage response and resistance mechanisms (APExBIO).

Biological Rationale

Poly (ADP-ribose) polymerase (PARP) enzymes are central to the DNA damage response, facilitating base excision repair and programmed cell death. Inhibiting PARP activity disrupts DNA repair in cancer cells, especially those with homologous recombination defects such as BRCA1 mutations. The rationale for targeting PARP in breast cancer is based on synthetic lethality: cells deficient in BRCA1 or BRCA2 are hypersensitive to PARP inhibitors, leading to selective tumor cell death (Schwartz 2022). Overcoming P-glycoprotein (Pgp)-mediated drug resistance is also a priority, as efflux mechanisms limit the efficacy of many chemotherapeutics and PARP inhibitors. AZD2461 was engineered to address these resistance mechanisms while maintaining high potency against PARP-1.

Mechanism of Action of AZD2461

AZD2461 is a small molecule (molecular weight 395.43, C₂₂H₂₂FN₃O₃) that binds PARP-1 and inhibits its enzymatic activity with an IC50 of 5 nM (APExBIO). In breast cancer cell lines MCF-7 and SKBR-3, AZD2461 exposure (5–50 μM, 48–72 h) reduces viable cell counts in a concentration- and time-dependent manner. Mechanistically, it induces G2 phase cell cycle arrest, observed as an increased G2 population and decreased S-phase fraction. In vivo, AZD2461 administration in KB1P tumor-bearing mice results in complete PARP inhibition for several hours, with restoration of PAR levels by 24 hours. Its lower affinity for Pgp allows it to bypass common drug efflux resistance pathways, distinguishing it from earlier agents like olaparib (AZD2281.com).

Evidence & Benchmarks

• AZD2461 inhibits PARP-1 enzyme activity in vitro with an IC50 of 5 nM (Schwartz 2022, https://doi.org/10.13028/wced-4a32).
• In MCF-7 and SKBR-3 breast cancer cells, AZD2461 (5–50 μM, 48–72 h) reduces viable cell numbers in a concentration- and time-dependent manner (Schwartz 2022, https://doi.org/10.13028/wced-4a32).
• AZD2461 treatment increases G2 cell cycle fraction and decreases S-phase fraction, consistent with cell cycle arrest (Schwartz 2022, https://doi.org/10.13028/wced-4a32).
• In vivo, AZD2461 administration to KB1P tumor-bearing mice achieves complete PARP inhibition for several hours; PAR levels return to baseline at 24 h (APExBIO, product page).
• AZD2461 displays reduced Pgp affinity compared to olaparib, supporting efficacy in Pgp-expressing, drug-resistant tumor models (APExBIO, product page).
• Long-term dosing in mice is well tolerated and doubles median relapse-free survival from 64 to 132 days (APExBIO, product page).

For a broader context and comparative workflow strategies, see this guide (which focuses on general PARP inhibitor workflows, while the present article updates efficacy data for AZD2461 in overcoming Pgp-mediated resistance), this resource (which details translational applications; here we focus on quantitative benchmarks), and this article (which provides troubleshooting, whereas the current review clarifies the experimental evidence and mechanism of action for AZD2461).

Applications, Limits & Misconceptions

AZD2461 is suited for:

• Cellular studies of DNA repair, PARP signaling, and programmed cell death in breast cancer.
• Elucidating resistance mechanisms, especially Pgp-mediated drug efflux in BRCA1-mutated tumor models.
• In vitro and in vivo pharmacology assays on cell cycle, cytotoxicity, and relapse-free survival.

Common Pitfalls or Misconceptions

• AZD2461 is not water soluble; DMSO or ethanol (ultrasound-assisted) are required for stock solutions (APExBIO).
• It is not effective for all tumor types; efficacy is best established in BRCA1-deficient and Pgp-expressing breast cancer models (Schwartz 2022).
• AZD2461 is a research-use-only reagent; it is not approved for clinical or therapeutic use in humans.
• Long-term solution stability is limited; store solid at -20°C and prepare fresh solutions for each experiment.
• PARP inhibition is reversible; full PAR activity recovers within 24 h post-dosing in vivo.

Workflow Integration & Parameters

For in vitro assays, AZD2461 is typically used at 5–50 μM for 48–72 hours in breast cancer cell lines. Stock solutions should be prepared in DMSO (≥16.35 mg/mL) or ethanol (≥45.2 mg/mL, with ultrasound), and aliquots stored at -20°C. For in vivo studies in mice, dosing regimens should be optimized to achieve complete PARP inhibition and monitor recovery of PAR levels within 24 hours. Relapse-free survival endpoints are recommended for preclinical efficacy studies. APExBIO provides validated protocols and technical support for AZD2461 (A4164) here.

Conclusion & Outlook

AZD2461 is a next-generation PARP inhibitor with nanomolar potency, robust activity in BRCA1-mutated and Pgp-expressing breast cancer models, and the capacity to double relapse-free survival in preclinical settings. Its low Pgp affinity overcomes a major resistance mechanism, positioning AZD2461 as an indispensable tool for research on DNA repair, drug resistance, and cancer relapse prevention. For the most up-to-date workflows and troubleshooting, consult APExBIO and recent literature. The continued development and application of AZD2461 will inform future strategies in precision oncology and PARP inhibitor therapy.